{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-007107","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.214094+00:00","generated_at":"2026-05-28T01:20:16.749434+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion pivots to diabetes & obesity; icovamenib shows 1.5% HbA1c drop in insulin-deficient patients","bullets":["Placebo-adjusted 1.5% mean HbA1c reduction in severe insulin-deficient T2D patients after 12 weeks of icovamenib, sustained 14 weeks off treatment.","Placebo-adjusted 1.0% HbA1c reduction in patients uncontrolled on GLP-1 therapies, consistent with preclinical synergy with semaglutide.","100% of severely insulin-deficient patients on 100 mg icovamenib responded with durable HbA1c decline; no drug-related adverse events.","Company plans to end oncology studies, seek partnerships, and focus on two late-stage trials: Phase 2/3 in insulin-deficient T2D and Phase 2b combo with GLP-1.","Novel oral menin inhibitor designed to regenerate beta cells; FDA discussions expected to support late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-007107","json":"https://secwatch.observer/filing/0001193125-25-007107.json","markdown":"https://secwatch.observer/filing/0001193125-25-007107.md","text":"https://secwatch.observer/filing/0001193125-25-007107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/0001193125-25-007107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/d830016d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:20:16.749434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}